Please assess the completion status of the following clinical trial:

Trial Title: A Study for Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Receiving oral antihyperglycemic medications (including metformin) without insulin injection in the last 90 days~* Hemoglobin A1c (HbA1c) equal to or greater than 7.0% but less than 11.0%~* Willing to receive insulin injection while continuing to take the prestudy oral antihyperglycemic medications~* Able to perform self monitoring of blood glucose~Exclusion Criteria:~* Are taking any other glucose-lowering agents other than metformin, sulfonylurea or Thiazolidinedione (Pioglitazone)~* Have taken acarbose, miglitol, pramlintide, exenatide, repaglinide, or nateglinide in the past 6 weeks, or for a total of 30 days or more, in the last 24 weeks~* Have a body mass index greater than 35 kg/m2~* History or presence of kidney disease~* Have cardiac disease (Class III or IV)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Insulin lispro low mixture (Type: EXPERIMENTAL): Insulin lispro low mixture (1, 2 or 3 daily injections)
- Insulin glargine (Type: ACTIVE_COMPARATOR): Insulin glargine (alone or with 1, 2 or 3 daily injections of insulin lispro)

Based on this trial design, predict the completion outcome and termination type (if applicable).